Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Astera Labs reported record Q1 2026 revenue of $308.4 million, up 14% sequentially and 93% year-over-year, driven by strong demand for its PCIe 6 connectivity portfolio. GAAP gross margin was 76.3%, with GAAP net income of $80.3 million and diluted EPS of $0.44.
On a non-GAAP basis, operating margin reached 36.2% and diluted EPS was $0.61. For Q2 2026, the company guides revenue to $355–$365 million, GAAP diluted EPS of $0.44–$0.46, and non-GAAP diluted EPS of $0.68–$0.70, indicating continued rapid growth in AI infrastructure demand.
Astera Labs, Inc. (ALAB) will hold its 2026 annual stockholder meeting on June 4, 2026 at its San Jose headquarters. Stockholders of record as of April 13, 2026 may vote on four items: electing three Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, an advisory Say-on-Pay vote on named executive officer compensation, and an advisory vote on Say-on-Pay frequency, with the board recommending an annual vote.
The company highlights a classified board structure, majority-independent directors, and fully independent audit, compensation, and nominating committees. In 2025, non-employee directors received cash retainers plus RSU grants, while executives were paid through salary, annual cash incentives tied 50/50 to revenue and non-GAAP operating margin, and long-term RSUs. Strong 2025 performance led to annual incentives paying at 180.586% of target, producing a $1.33 million bonus for each of the CEO and COO. PwC audit and related fees totaled $3.88 million for 2025. The board is adding performance-based RSUs from 2026 and maintains stock ownership guidelines, an insider trading policy, and a clawback policy.
Astera Labs, Inc. director and CEO Mohan Jitendra reported that a living trust associated with him sold 335,881 shares of Common Stock in open-market transactions. The sales occurred on April 17 and April 20, 2026 at weighted average prices generally in the high $160s to mid-$170s per share.
The transactions were executed automatically under a Rule 10b5-1 trading plan adopted on December 1, 2025. The filing notes that the shares are held by a living trust and other estate planning trusts, and Jitendra disclaims beneficial ownership of these securities except to the extent of any pecuniary interest, while still reporting more than 4.3 million shares held indirectly after the sales.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported open-market sales of Astera Labs common stock totaling 24,998 shares. The transactions on April 17 and April 20, 2026 were executed at weighted average prices around $175.00–$175.51 per share.
Entities associated with Dyckerhoff, including a trust and a limited partnership, sold shares, and he also sold shares held directly. Footnotes state the shares held by these entities are in trusts and a partnership where he disclaims beneficial ownership except for his pecuniary interest.
The filing notes that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
ALAB submitted a Form 144 notice for proposed sales of Common stock on 04/17/2026 relating to shares held or acquired in prior private placements and distributions. The filing lists broker/dealer Stifel (501 N Broadway, St. Louis) and multiple grant/purchase dates with share counts tied to those issuances.
Astera Labs, Inc. reported multiple proposed and completed sales of Common Stock by related parties under Rule 144 and transfers of issued shares. The filing lists transfers to Jitendra Mohan (71,730 RSUs on 12/01/2025; 340,770 Founder Shares on 11/21/2017) and four reported sales during Feb–Apr 2026 totaling 433,188 shares with disclosed gross proceeds: $11,758,145.75, $20,723,774, $18,522,450, and $518,036.
The notices identify Jitendra Mohan and the Mohan & Samant 2022 Living Trust as sellers and show transactions dated 02/17/2026, 03/17/2026, 04/10/2026, and 04/15/2026. The filing is a disclosure of affiliate sales activity rather than company-operated offers.
Astera Labs, Inc. Chief Executive Officer Mohan Jitendra, through a living trust, reported open-market sales of Common Stock. On April 15, 2026, the living trust sold 2,767 shares at $174.5682 per share and 200 shares at $175.03 per share.
The filing states these sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025, indicating they were scheduled in advance. Following the trades, the living trust holds 4,405,015 shares, and the filing also lists additional indirect holdings in multiple estate-planning trusts and a direct holding of 1,452,739 shares of Common Stock.
Astera Labs submitted a Form 144 notice reporting proposed transfers of common stock by Jitendra Mohan and related trust. The excerpt lists four planned transfers dated 12/01/2025 totaling 204,750 shares from RSU issuances, and three sales filed as completed in the past three months: 94,971, 157,500, and 123,750 shares with corresponding gross proceeds shown.
Astera Labs, Inc. reported that a living trust associated with Chief Executive Officer Mohan Jitendra sold 123,750 shares of Common Stock in open-market transactions. The trust sold 99,023 shares at a weighted average price of $149.5322 per share and 24,727 shares at a weighted average price of $150.2535 per share.
The filing states these sales occurred automatically under a Rule 10b5-1 trading plan adopted on December 1, 2025. After the sales, the living trust reported holding 4,407,982 shares indirectly, and the filing also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly.